Sign in Subscribe
Cancer

Oncolytic Virotherapy Shows Promise in Cancer Treatment with Adenoviruses

Strategic Insights

— 1 min read

Recent research published in the Molecular Therapy Oncology journal has highlighted the potential of oncolytic adenoviruses in treating a wide range of tumors. According to the study, these viruses have shown to be effective in hijacking cellular machinery and influencing the acetylome of the host genome. The researchers from the University of Texas MD Anderson Cancer Center aim to explore the opportunities of combining acetylation modifiers with oncolytic adenoviruses to further improve patient outcomes.

Key Takeaways:

  • Adenoviruses are highly immunogenic agents that have shown promise in gene delivery vectors and oncolytic viruses, with over 30% of cancer virotherapy clinical trials featuring them.
  • Due to their effective cellular uptake and hijack of cellular machinery, replication-competent adenoviruses are promising therapeutic agents for treating a wide range of tumors.
  • The influence of adenoviral acetylome regulation on host cell acetylome regulation has regained attention, making them potentially desirable therapeutic agents for cancers driven by epigenetic modifications.
  • The study aims to cover the viral processes influencing the acetylome of the host genome and discuss the effect of differential acetylation on antiviral defense mounted by the host immune system.
  • The research has been peer-reviewed and published in the Molecular Therapy Oncology journal.
  • Funding for the research includes the National Institutes of Health (NIH), ChadTough Defeat DIPG Foundation, Alliance for Cancer Gene Therapy, Chance for Life Foundation, Cure Starts Now Foundation, and the Bradley Zankel Foundation.

Statistics:

  • Over 30% of cancer virotherapy clinical trials feature oncolytic adenoviruses.
  • The study aims to explore the opportunities of combining acetylation modifiers with oncolytic adenoviruses to further improve patient outcomes.
  • The manufacturing of oncolytic adenoviruses is challenging due to the maintenance of viral replication capacity and specific targeting of cancer cells.
  • The oncolytic adenovirus therapy market is expected to grow significantly in the coming years due to the increasing adoption of targeted therapies in cancer treatment.
  • The number of clinical trials involving adenoviruses has increased from 2015 to 2020, indicating a growing interest in oncolytic virotherapy.

Sources:

  • The Multilayered Control of Acetylation During Adenovirus-based Immunotherapy of Cancer. Molecular Therapy Oncology, 2025;33(2).
  • NewsRx. Reports on Oncolytic Virotherapy from University of Texas MD Anderson Cancer Center Provide New Insights (The Multilayered Control of Acetylation During Adenovirus-based Immunotherapy of Cancer). Cancer Weekly. June 24, 2025; p 41.

Read more